Non-alcoholic Fatty Liver Disease research hub

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

This study is looking into a new medicine called efinopegdutide for a liver condition called MASH. We want to see if it can help reduce liver fat, swelling, and scarring in people with MASH and mild scarring. It also checks how safe the medicine is.

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

This study is testing a new drug called ALN-CIDEB for people with fatty liver conditions, MASLD and MASH. It aims to check how safe the drug is, if it causes side effects, and how it affects liver fat.

COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study

This study looks at how hormone replacement therapy (HRT) affects fat in the liver and body in women going through menopause. Researchers want to understand if HRT can help prevent or manage fatty liver disease, a common problem after menopause.

The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

This study looks at whether a daily pectin supplement, found in foods like citrus peel, can reduce inflammation and improve gut health in adults with a common liver condition called MASLD. Researchers want to see if it helps with overall health.

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.

Digital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)